Kastenmayer James Paul 4

What Happened

• Kastenmayer James Paul, General Counsel of ArriVent BioPharma (AVBP), received a derivative equity award on Feb 2, 2026 for 130,000 shares. The Form 4 lists the acquisition price as $0.00 and treats the grant as a derivative transaction (code A). This is an equity award/option grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (appears timely under the 2-business-day Form 4 rule).
• Type: Award/Grant (derivative security), Transaction code A.
• Shares/units granted: 130,000; price listed on filing: $0.00 (derivative).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnote: The shares underlying this option vest 25% on Feb 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service (per footnote F1).

Context

• This is a compensation award (an option/derivative grant) and not an open-market buy or sale — it does not by itself represent immediate buying or selling pressure. Vesting is time-based and contingent on continued service, so the economic interest will accrue over the next several years as vesting occurs.